Abstract:BackgroundPositiveallosteric modulators of GABAA receptors transduce a host ofbeneficial effects but can have motor and sedative liabilities. A benzodiazepine, HZ‐166, had previously been characterized as an alpha 2,3‐selective GABAA receptor modulator with anticonvulsant, anxiolytic, and anti‐nociceptive properties but reduced motor effects. However, the ester moiety in HZ‐166 quickly metabolizes to the carboxylic acid leading to variable exposures of ester in plasma and brain. Moreover, the acid of HZ‐166 possesses significant invitro activity and may well contribute to efficacy seen in in vivo models. We have identified five membered ringheterocycles (oxazoles, dioxazoles) as competent ester replacements which lend themselves to comparable in vitro potency, reduced metabolic complications, consequently leading to an overall increase in unbound central concentration and thus increased efficacy in animal models of pain and epilepsy.MethodsPlasmaand brain exposures of compounds were assessed after i.p. dosing. Compounds were evaluated for efficacy inseveral rodent seizure‐induction models. We also evaluated the anti‐nociceptive effects of one compound (KRM‐II‐81)in rats exposed to chronic pain induced by spinal nerve ligation (SNL) (L5/6)by the Von Frey test. Finally,assessment of motor impairment was evaluated on the inverted screen test.ResultsKRM‐II‐81which utilizes a bioisosteric oxazole as a five membered ring heterocycle replacementof the ester in HZ‐166 did not negatively affect selectivity for α 3(0.97 μM) over α 1 (> 20 μM). However, KRM‐II‐81 demonstrated enhancedbrain exposure versus HZ‐166 after systemic administration. Accordingly, unbound mouse brain exposure exhibited by KRM‐II‐81 after 1 hr (10 mg/kg, i.p.) was 978 nM. In contrast, HZ‐166 possessed >100 folddecrease in mouse unbound brain concentration (6.4 nM) when dosed under the same conditions. Increased central exposure translated to increased efficacy without induction of motor side effects. KRM‐II‐81 (30 mg/kg, i.p.) was fully protective against pentylenetetrazole (PTZ)‐induced clonic convulsions in rats (ED50 = 10.2 mg/kg), whereas HZ‐166 was only partially effective. Further, whereas HZ‐166 (up to 60 mg/kg, i.p.) was ineffective in increasing the dose of i.v.‐infused PTZ required for convulsions, KRM‐II‐81 was efficacious at a dose as low as 10 mg/kg. HZ‐166 was also not active against electroshock‐induced convulsions in mice while KRM‐II‐81 showed efficacy at 30 mg/kg. KRM‐II‐81 also increased pain thresholds by ~2.5 times, an effect equivalent to gabapentin without observable changes in sedation or motor impairment. Brains from SNL rats exhibited decreases in K+‐evoked glutamate release.ConclusionsSubstitution of an oxazole bioisostere for the ester in HZZ‐166 did not affect selectivity α subtype selectivity but significantly increased mouse brain exposure after systemic dosing. Increased brain exposure translated to increased potency and efficacy in rodent seizure‐induction models as well as efficacy against nociceptive challenge in a rodent chronic pain model. In addition, motor side‐effects were not exacerbated by KRM‐II‐81. Thus, KRM‐II‐81 represents a significant advance in the pharmacology of the GABAa receptor.

Allosteric Modulation of Sigma-1 Receptors Elicits Anti-Seizure Activities.

SKF83959 is a Potent Allosteric Modulator of Sigma-1 Receptor

Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects.

Allosteric Modulation of Sigma‐1 Receptors Elicits Rapid Antidepressant Activity

Allosteric Modulation of Sigma‐1 Receptors by SKF83959 Inhibits Microglia‐mediated Inflammation

Schisandrin B, a dual positive allosteric modulator of GABA A and glycine receptors, alleviates seizures in multiple mouse models

The classical D1 dopamine receptor antagonist SCH23390 is a functional sigma-1 receptor allosteric modulator

Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases

Preclinical efficacy profiles of the sigma‐1 modulator E1R and of fenfluramine in two chronic mouse epilepsy models

LPM682000012, a Synthetic Neuroactive Steroid That Ameliorates Epileptic Seizures by Downregulating the Serpina3n/NF-κB Signaling Pathway

Cannabinoid‐like compounds found in non‐cannabis plants exhibit antiseizure activity in genetic mouse models of drug‐resistant epilepsy

SKF83959 Suppresses Excitatory Synaptic Transmission in Rat Hippocampus Via a Dopamine Receptor-Independent Mechanism.

Pharmacological Analysis of GABAA Receptor and Sigma1R Chaperone Interaction: Research Report I-Investigation of the Anxiolytic, Anticonvulsant and Hypnotic Effects of Allosteric GABAA Receptors' Ligands

Arylbenzazepines Are Potent Modulators for the Delayed Rectifier K+ Channel: A Potential Mechanism for Their Neuroprotective Effects

A Novel, A-2, 3-Selective Gaba(A) Receptor Modulator with Improved Central Penetrability and Associated Antiepileptic and Anti-Pain Efficacy

A peptide blocking the ADORA1-neurabin interaction is anticonvulsant and inhibits epilepsy in an Alzheimer's model

Synthesis and Pharmacological Evaluation of Novel Benzenesulfonamide Derivatives As Potential Anticonvulsant Agents.

Discovery of 7-alkyloxy- [1,2,4] triazolo[1,5-a] pyrimidine derivatives as selective positive modulators of GABAA1 and GABAA4 receptors with potent antiepileptic activity

3 β-Methyl-Neurosteroid Analogs Are Preferential Positive Allosteric Modulators and Direct Activators of Extrasynaptic δ-Subunit γ-Aminobutyric Acid Type A Receptors in the Hippocampus Dentate Gyrus Subfield

Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept

The atypical dopamine receptor agonist SKF 83959 enhances hippocampal and prefrontal cortical neuronal network activity in a rat model of cognitive dysfunction